Wajant H - Search Results

1

ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade.

Silence K, Dreier T, Moshir M, Ulrichts P, Gabriels SM, Saunders M, Wajant H, Brouckaert P, Huyghe L, Van Hauwermeiren T, Thibault A, De Haard HJ. Silence K, et al. Among authors: wajant h. MAbs. 2014 Mar-Apr;6(2):523-32. doi: 10.4161/mabs.27398. Epub 2013 Dec 6. MAbs. 2014. PMID: 24492296 Free PMC article.

2

A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo.

Trebing J, Lang I, Chopra M, Salzmann S, Moshir M, Silence K, Riedel SS, Siegmund D, Beilhack A, Otto C, Wajant H. Trebing J, et al. Among authors: wajant h. MAbs. 2014 Jan-Feb;6(1):297-308. doi: 10.4161/mabs.26709. MAbs. 2014. PMID: 24135629 Free PMC article.

3

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.

Trebing J, El-Mesery M, Schäfer V, Weisenberger D, Siegmund D, Silence K, Wajant H. Trebing J, et al. Among authors: wajant h. Cell Death Dis. 2014 Jan 30;5(1):e1035. doi: 10.1038/cddis.2013.555. Cell Death Dis. 2014. PMID: 24481449 Free PMC article.

4

Therapeutic targeting of CD70 and CD27.

Wajant H. Wajant H. Expert Opin Ther Targets. 2016 Aug;20(8):959-73. doi: 10.1517/14728222.2016.1158812. Epub 2016 Mar 15. Expert Opin Ther Targets. 2016. PMID: 26914723 Review.

5

Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins.

Kums J, Nelke J, Rüth B, Schäfer V, Siegmund D, Wajant H. Kums J, et al. Among authors: wajant h. MAbs. 2017 Apr;9(3):506-520. doi: 10.1080/19420862.2016.1274844. Epub 2017 Jan 17. MAbs. 2017. PMID: 28095113 Free PMC article.

6

CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.

Nelke J, Medler J, Weisenberger D, Beilhack A, Wajant H. Nelke J, et al. Among authors: wajant h. MAbs. 2020 Jan-Dec;12(1):1807721. doi: 10.1080/19420862.2020.1807721. MAbs. 2020. PMID: 32840410 Free PMC article.

7

Tumor therapeutics by design: targeting and activation of death receptors.

Wajant H, Gerspach J, Pfizenmaier K. Wajant H, et al. Cytokine Growth Factor Rev. 2005 Feb;16(1):55-76. doi: 10.1016/j.cytogfr.2004.12.001. Cytokine Growth Factor Rev. 2005. PMID: 15733832 Review.

8

Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.

Wyzgol A, Müller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, Wajant H. Wyzgol A, et al. Among authors: wajant h. J Immunol. 2009 Aug 1;183(3):1851-61. doi: 10.4049/jimmunol.0802597. Epub 2009 Jul 13. J Immunol. 2009. PMID: 19596991

9

Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis.

Chopra M, Riedel SS, Biehl M, Krieger S, von Krosigk V, Bäuerlein CA, Brede C, Jordan Garrote AL, Kraus S, Schäfer V, Ritz M, Mattenheimer K, Degla A, Mottok A, Einsele H, Wajant H, Beilhack A. Chopra M, et al. Among authors: wajant h. Carcinogenesis. 2013 Jun;34(6):1296-303. doi: 10.1093/carcin/bgt038. Epub 2013 Feb 5. Carcinogenesis. 2013. PMID: 23385062

10

TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes.

Salzmann S, Lang I, Rosenthal A, Schäfer V, Weisenberger D, Carmona Arana JA, Trebing J, Siegmund D, Neumann M, Wajant H. Salzmann S, et al. Among authors: wajant h. J Immunol. 2013 Sep 1;191(5):2308-18. doi: 10.4049/jimmunol.1202899. Epub 2013 Aug 5. J Immunol. 2013. PMID: 23918987

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

215 results

Search Page

Filters